BR112022005343A2 - Trazodona ou um sal da mesma para uso em um método para tratar insônia, composição farmacêutica, xarope, e, método para tratar insônia - Google Patents
Trazodona ou um sal da mesma para uso em um método para tratar insônia, composição farmacêutica, xarope, e, método para tratar insôniaInfo
- Publication number
- BR112022005343A2 BR112022005343A2 BR112022005343A BR112022005343A BR112022005343A2 BR 112022005343 A2 BR112022005343 A2 BR 112022005343A2 BR 112022005343 A BR112022005343 A BR 112022005343A BR 112022005343 A BR112022005343 A BR 112022005343A BR 112022005343 A2 BR112022005343 A2 BR 112022005343A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating insomnia
- trazodone
- syrup
- salt
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962906166P | 2019-09-26 | 2019-09-26 | |
| PCT/EP2020/077017 WO2021058810A1 (en) | 2019-09-26 | 2020-09-25 | Pediatric trazodone compositions and method of treatment thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022005343A2 true BR112022005343A2 (pt) | 2022-06-14 |
Family
ID=72665264
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022005343A BR112022005343A2 (pt) | 2019-09-26 | 2020-09-25 | Trazodona ou um sal da mesma para uso em um método para tratar insônia, composição farmacêutica, xarope, e, método para tratar insônia |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12514856B2 (enExample) |
| EP (1) | EP4034117A1 (enExample) |
| JP (1) | JP7629453B2 (enExample) |
| KR (1) | KR102936358B1 (enExample) |
| CN (1) | CN114615983A (enExample) |
| AU (1) | AU2020354534B2 (enExample) |
| BR (1) | BR112022005343A2 (enExample) |
| CA (1) | CA3153639A1 (enExample) |
| GE (2) | GEP20257739B (enExample) |
| IL (1) | IL291548A (enExample) |
| MX (1) | MX2022003442A (enExample) |
| UA (1) | UA129270C2 (enExample) |
| WO (1) | WO2021058810A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240173315A1 (en) * | 2022-11-14 | 2024-05-30 | OWP Pharmaceuticals, Inc. | Trazodone oral solution |
| US20240390277A1 (en) * | 2023-04-15 | 2024-11-28 | Rubicon Research Private Limited | Liquid formulations of trazodone |
| CN119280155B (zh) * | 2024-12-11 | 2025-02-25 | 新基元(北京)医药科技有限公司 | 一种改善稳定性的盐酸曲唑酮液体药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1931346T1 (sl) | 2005-09-09 | 2012-10-30 | Angelini Labopharm Llc | Trazodonski sestavek za dajanje enkrat dnevno |
| ITMI20071573A1 (it) * | 2007-07-31 | 2009-02-01 | Acraf | Composizione farmaceutica liquida stabile a base di trazodone |
| ITMI20071603A1 (it) | 2007-08-03 | 2009-02-04 | Acraf | Trazodone e trazodone cloridrato in forma purificata |
-
2020
- 2020-09-25 MX MX2022003442A patent/MX2022003442A/es unknown
- 2020-09-25 UA UAA202201314A patent/UA129270C2/uk unknown
- 2020-09-25 AU AU2020354534A patent/AU2020354534B2/en active Active
- 2020-09-25 CA CA3153639A patent/CA3153639A1/en active Pending
- 2020-09-25 GE GEAP202015936A patent/GEP20257739B/en unknown
- 2020-09-25 KR KR1020227011618A patent/KR102936358B1/ko active Active
- 2020-09-25 EP EP20781357.7A patent/EP4034117A1/en active Pending
- 2020-09-25 JP JP2022518971A patent/JP7629453B2/ja active Active
- 2020-09-25 WO PCT/EP2020/077017 patent/WO2021058810A1/en not_active Ceased
- 2020-09-25 BR BR112022005343A patent/BR112022005343A2/pt unknown
- 2020-09-25 GE GEAP202415936A patent/GEAP202415936A/en unknown
- 2020-09-25 CN CN202080066712.7A patent/CN114615983A/zh active Pending
- 2020-09-25 US US17/763,037 patent/US12514856B2/en active Active
-
2022
- 2022-03-21 IL IL291548A patent/IL291548A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022549473A (ja) | 2022-11-25 |
| IL291548A (en) | 2022-05-01 |
| JP7629453B2 (ja) | 2025-02-13 |
| CA3153639A1 (en) | 2021-04-01 |
| GEAP202415936A (en) | 2024-10-28 |
| WO2021058810A1 (en) | 2021-04-01 |
| MX2022003442A (es) | 2022-07-11 |
| GEP20257739B (en) | 2025-02-25 |
| US12514856B2 (en) | 2026-01-06 |
| KR102936358B1 (ko) | 2026-03-10 |
| EP4034117A1 (en) | 2022-08-03 |
| KR20220080096A (ko) | 2022-06-14 |
| US20220331312A1 (en) | 2022-10-20 |
| UA129270C2 (uk) | 2025-03-05 |
| AU2020354534B2 (en) | 2025-10-02 |
| CN114615983A (zh) | 2022-06-10 |
| AU2020354534A1 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022003514A2 (pt) | Degradadores bifuncionais de brd9 e seus métodos de uso | |
| CL2019000268A1 (es) | Composición de cannabis. | |
| BR112021021637A2 (pt) | Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório | |
| PE20170673A1 (es) | Terapia de combinacion para tratar una paramixovirus | |
| MX2022000453A (es) | Compuestos útiles para tratar infecciones por virus de influenza. | |
| MX2019002265A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| BR112021018262A2 (pt) | Tratamento de doenças e distúrbios mitocondriais associados, incluindo sintomas dos mesmos usando pridopidina | |
| BR112022020643A2 (pt) | Método de tratamento de esteato-hepatite não alcoólica | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| BR112018011700A2 (pt) | ?moduladores de canais de kv3 para tratar dor? | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| Alcocer‐Gómez et al. | Effect of coenzyme Q10 on psychopathological symptoms in fibromyalgia patients | |
| BR112022008000A2 (pt) | Derivado de pirazol-heteroarila, método de preparação para o mesmo e uso médico do mesmo | |
| BR112018017233A2 (pt) | uso de i. butyriciproducens e/ou e. hallii, e, composição | |
| BR112022001815A2 (pt) | Método para tratar doença de alzheimer por meio da regulação de micro-organismos intestinais | |
| BR112022021640A2 (pt) | Usos e formulações de canabinoides | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| CO2021005797A2 (es) | Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia | |
| MX2022003442A (es) | Composiciones de trazodona pediatrica y metodo de tratamiento con las mismas. | |
| BR112018006276A2 (pt) | composto, composição farmacêutica, e, inibidor de subunidade gyrb da dna girase e/ou subunidade pare de topoisomerase iv. | |
| BR112019001948A2 (pt) | método de tratamento de um indivíduo humano. | |
| BR112017021589A2 (pt) | métodos para o tratamento de transtornos cardiovasculares | |
| BR112022015046A2 (pt) | Uso de forsitina e/ou seus derivados, método para a inibição da proteína 3clpro do vírus covid-19, uso de composição de forsitina/forsitosídeo, métodos para uso contra o vírus covid-19 ou para o tratamento de doenças causadas pelo vírus covid-19, composição de forsitina/forsitosídeo e medicamento compreendendo uma composição de forsitina/forsitosídeo | |
| BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
| BR112022015608A2 (pt) | Fetuína-a para o tratamento de transtornos renais |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |